Slide 1: TAKE Solutions Limited
TAKE Solutions Limited Delivering Domain-intensive Services In Life Sciences And Supply Chain Management
Slide 2: At A Glance
At A Glance 17 7 Europe HQ: Frankfurt, Offices Countries Germany Major trial operations center in Germany and USA HQ: Princeton, NJ sites through Europe Clinical, Regulatory & Safety consulting and Specialists in UK, Sweden, Germany, 15,872 1,500+ Poland, Denmark, Russia technology centers. and othe
Slide 3: TAKE is a preferred partner for Life Sciences Companies
TAKE is a preferred partner for Life Sciences Companies , Improving Efficiency And Driving Better Outcomes Across The Drug Development Value Chain
Slide 4: Life Sciences Drug Development Landscape
Life Sciences Drug Development Landscape US $1 – 1.5 Billion per Drug! Bringing a drug to the market is a complex process involving many time consuming and Drug Discovery Pre-clinical Trials Clinical Trials (Phase I to III) Regulatory Approval Post-approval expensive stages ~ 5 Years ~ 1 Year ~ 7 Ye
Slide 5: Where Do We Come In?
Where Do We Come In? US $1 – 1.5 Billion per Drug! Drug Discovery Pre-clinical Trials Clinical Trials (Phase I to III) Regulatory Approval Post-approval ~ 5 Years ~ 1 Year ~ 7 Years ~ 1.5 Years On Going Basic Research (R&D) Molecule formulation (compound) is identified to combat a disease Clinical T
Slide 6: Life Sciences
As a strategic partner, TAKE Solutions delivers full-service Clinical, Regulatory and Safety services and solutions to the Life Sciences Industry LIFE SCIENCES
Slide 7: Need for Outsourcing in Life Sciences
Need for Outsourcing in Life Sciences A paradigm shift is taking place in Life Sciences R&D R&D Marketing & Clinical Marketing & Clinical Branding Research Branding Research Sponsor Sponsor Company Company Regulatory Regulatory Manufacturing Manufacturing Affairs Outsourced Affairs Safety (PV) Inhou
Slide 8: Life Sciences Outsourcing
Life Sciences Outsourcing An Attractive Growth Opportunity Life Sciences Outsourcing The USD 32 Bn Life Sciences USD 32 Bn Outsourcing Industry will (2017) reach USD 39 Bn by 2020 Life Sciences Outsourcing Clinical 6% USD 39.1 Bn $27.6 Bn (2017) to $32.9 Bn (2020) CAGR (2020) Regulatory 11.5% $2.6 B
Slide 9: Types of Sponsors
Types of Sponsors Who is Outsourcing? Although Large Innovators account for the majority, Mid / Small Innovators are an equally attractive segment in this space! Generics accounts for 10% The Mid/Small Innovators Large Innovators (Turnover >US$ 5Bn) (Turnover US$ 1-5 Bn) account are responsible for
Slide 10: Why Do Sponsors Choose Us?
Why Do Sponsors Choose Us? Our Unique Formula = Technology Platform Based Services + Knowledge Partner Clinical Regulatory Capabilities Services across Full Operational Capabilities Markets Nets Industry Forums Technology Consulting Experts Across The Globe Innovative Platforms Safety Offering both
Slide 11: We Deliver Results
We Deliver Results Consistently Recognized as a Leader in Life Sciences 120+ 2017 – Leader in IDC MarketScape: Worldwide Life Science Drug Network Members Safety Services 4000+ 330+ Sites 100000+ Clinical Regulatory 2013 – Leader in IDC MarketScape on Drug Safety Services Trials Worldwide Life Scien
Slide 12: Our Life Sciences Journey
Our Life Sciences Journey We have built our Clinical, Regulatory and Safety offerings organically … Regulatory Regulatory Clinical Regulatory Capabilities Capabilities Capabilities across across Services Services Markets Services across Markets Nets Markets Nets Consulting Consulting Technology Safe
Slide 13: We deliver high-quality, global trials enabled by our proprietary eClinical platform
100+ Innovator and Generics Sponsors We deliver High-quality, global trials 330+ Clinal Trials enabled by our proprietary eClinical platform 1000+ BA/BE & Lab Studies Conducted Clinical Trials for the Conducted USPTO Patent for “Method for 1st Stem Cell Product in the 7% of All Biosimilars Trials in
Slide 14: Key Clinical Offerings
Key Clinical Offerings For Heads of Clinical Operations, focused Medical on sharing best practice to define Bioavailability & Imaging excellence in delivery of clinical trials Bioequivalence Services Studies Biologics & Biosimilars OneClinical Studies Full Service Our Optimized eClinical and Analyti
Slide 15: How Do We Help Our Clients?
How Do We Help Our Clients? Full-service phase II stem cell therapy study Business Need Results Sponsor required a full- service phase II stem cell 1st stem cell-based study in a rare patient pool biological product with high screen fail rate approved by DCGI “ We Greatly Appreciate the valued contr
Slide 16: We help life sciences companies Stay Compliant
Submissions Across 130+ Countries 10,000+ Paper Submissions 46,000+ We help life sciences eCTD companies Stay Compliant 100,000+ Global Regulatory 15,000+ Submissions* Nees 5+ USA, APAC & Unique Technology Submitted Propositions LATAM 8% of Total Regulatory Regulatory Hubs Submissions to USFDA 2012-
Slide 17: Key Regulatory Offerings
Key Regulatory Offerings For Labeling Professionals; focused on the full lifecycle of labeling For Regulatory Information Management (RIM) professionals to develop best practices Regulatory and leading edge solutions for RIM Information Submissions Management & Report with over 150 clients, is a Pub
Slide 18: How Do We Help Our Clients?
How Do We Help Our Clients? Global publishing and submission management for top 5 pharma Results Business Need • Successful delivery of 15-18k • Make 45k submissions submissions per annum annually across multiple • ~30% efficiency gain over health authorities baseline • Maintain quality and • 98% ac
Slide 19: Minimize Risks across the product lifecycle
We help life sciences companies Minimize Risks across the product lifecycle 30+ 100+ Years in PV Member Companies of our PV Networks We have successfully completed 300+ Safety Consulting Engagements www.takesolutions.com
Slide 20: Key Safety Offerings
Key Safety Offerings For Heads of Safety of Top 30 Life Sciences companies; invests in thought leadership to help shape future practices Adverse Event For Heads of Information Technology for PV departments, focused Reporting on increasing business value from technology investments Safety Risk For He
Slide 21: How Do We Help Our Clients?
How Do We Help Our Clients? Making a mid-size biotech compliant with latest EU regulation changes Results Business Need • The baseline benefit-risk profile of 200+ products was Upcoming regulatory changes established and is actively necessitated an overhaul of the monitored Safety systems to enable
Slide 22: Proud Partners
Small / Mid Clientele Innovators Generics Large Innovators Others Proud Partners across all Segments! 22 www.takesolutions.com
Slide 23: Leadership & Experts
Leadership & Experts Srinivasan H R D V Ravi Vice Chairman & MD Director Srinivasan HR, Founder of TAKE Solutions. He D.V. Ravi, Co-founder of TAKE Solutions. He is also the brings over 3 decades of leadership and has Managing Director of Shriram Capital, a financial services held significant leader
Slide 24: Supply Chain Management
_ SUPPLY CHAIN MANAGEMENT
Slide 25: Our Supply Chain Management Solutions
Our Supply Chain Management Solutions Supply Chain Collaboration Engineering Services Engineering Automate and streamline Sourcing Design & build high order-to-cash and procure- Smart global quality products to-pay processes through a sourcing programs with continuous central, easy to use without th
Slide 26: Business Performance
JSINESS ERFORMANCE =
Slide 27: Delivering Growth with Healthy Margins
Delivering Growth with Healthy Margins 18,000 23% 15,872 21% 16,000 20.5% 20.7% 19.5% 19.3% 19% 14,000 18.1% 13,446 EBITDA 17% Margins 12,000 29.5% 10,301 CAGR 15% 10,000 13% 8,000 7,304 Operating 11% Revenue 6,000 9% 4,000 3,065 7% 2,622 2,133 27.1% 2,000 1,494 CAGR EBITDA 5% - 3% FY15 FY16 FY17 FY
Slide 28: Region Wise Breakup
Region Wise Breakup Europe FY18 FY17 FY16 6.5% 7.4% 9.0% APAC FY18 FY17 FY16 Americas 13.4% 13.3% 17.0% FY18 FY17 FY16 80.1% 79.3% 74.0% % - Revenue Contribution 28 www.takesolutions.com
Slide 29: Capitalizing On The Potential For Life Sciences
Capitalizing On The Potential For Life Sciences 12% 18% 23% 29% 39% Life Sciences Revenue Growing by 88% 29.5% 77% 82% (CAGR) every year! 71% 61% 91% Revenue from Life Sciences FY14 FY15 FY16 FY17 FY18 (Q4 FY18) Life Sciences Supply Chain Management 29 www.takesolutions.com
Slide 30: Delivering Consistent Returns
Delivering Consistent Returns 19.1% 17.6% 15.3% 15.2% 14.0% RoNW 12.7% (Return on Net worth) 11.8% 12.5% 12.2% ROCE 10.9% (Return on Capital Employed) FY14 FY15 FY16 FY17* FY18** * - QIP dilution in FY17 ** - Preferential share allotment in FY18 30 www.takesolutions.com
Slide 31: TAKE uses platform-based services to provide 360 Degree Coverage of the life sciences domain
TAKE uses platform-based services to provide 360 Degree Coverage of the life sciences domain, Increasing Speed To Market and Reducing www.takesolutions.com Cost of drug development 31
Slide 32: Disclaimer
Disclaimer This presentation contains certain “forward-looking statements” concerning our future operations, prospects, strategies, financial condition, future economic performance (including growth and earnings), demand for our products and services and other statements of our plan, beliefs, expect
Slide 33: Thank You
THANK YOU www.takesolutions.com